Relmada Therapeutics, Inc. (RLMD)
NCM – Real Time Price. Currency in USD
6.69
+0.24 (3.72%)
At close: Jun 26, 2026, 4:00 PM EDT
6.69
-0.00 (-0.00%)
After-hours: Jun 26, 2026, 4:35 PM EDT
Find any stock by ticker or company name

NCM – Real Time Price. Currency in USD
6.69
+0.24 (3.72%)
At close: Jun 26, 2026, 4:00 PM EDT
6.69
-0.00 (-0.00%)
After-hours: Jun 26, 2026, 4:35 PM EDT
Revenue breakdown data has not been calculated yet.
No Data
There are no news for this stock.
Cash reserves $9.8M barely cover the upcoming debt maturities $0.0
Total current assets $235.3M exceed Total current liabilities $12.9M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$15.1M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 18.26 | 6.05 | 10 | |
| Quick ratio | 18.26 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Operating Income | -161M | -104M | -84M | -59M | -60M |
| Net Income | -157M | -99M | -80M | -57M | -59M |
| EBITDA | -161M | -104M | -84M | -59M | -60M |
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Gross margin % | N/A | -11.73 | 1.0 | |
| Operating margin % | N/A | -24.60 | 1.0 | |
| Net margin % | N/A | -172.20 | 1.0 | |
| EBITDA margin % | N/A | -201.27 | 1.0 | |
| Cash flow margin % | N/A | -156.39 | 1.0 | |
| Weighted average score | 1.0 | |||
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 33.49 | 5.5 |
| Next quarter | N/A | 33.31 | 5.5 |
| Current year | N/A | 42.99 | 5.5 |
| Next year | N/A | -16.73 | 1.0 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 4.11 | 18.52 | -3.22 | 6.0 |
| Y/Y | 999 | -8.49 | 62.07 | 16.6 | 7.5 |
| 3y average | 999 | 28.13 | 34.2 | 20.53 | 10 |
| 5y average | 999 | -10.39 | 8.13 | -36.34 | 4.5 |
| Weighted average score | 7.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |